Gene Editing Superstars Team Up to Make Cheaper Rare Disease Cures
Summarize this article with:
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the worldAmericas+1 212 318 2000EMEA+44 20 7330 7500Asia Pacific+65 6212 1000Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the worldAmericas+1 212 318 2000EMEA+44 20 7330 7500Asia Pacific+65 6212 1000Gene editing has the potential to cure thousands of people suffering from devastating rare diseases. But the Nobel Prize-winning technology faces a basic math problem: It’s not profitable to spend millions of dollars making a drug that may only treat one person.The solution, according to gene editing pioneer David Liu and his colleagues, is to bring everyone involved together — including patients, hospitals, scientists, drug companies and manufacturers — to make each step of the process simpler, faster and cheaper. Rather than the current bespoke method where each step is tailored and price tags can top $3 million, a collaborative approach may improve efficiency and allow the science to live up to its potential.